Add BrightSurf on Google Email

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)


Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

Researchers at DKFZ and UMM found that NK cells can impair the effect of cancer therapies using immune checkpoint inhibitors by controlling activated T cells. They identified B7H6 as a recognition molecule for NK cell attacks, which could limit excessive activation and expansion of T cells.

Precise localization of miniature robots and surgical instruments inside the body

A team at the German Cancer Research Center has developed a new method for precise localization of miniature robots and surgical instruments, enabling real-time tracking and control. This breakthrough could advance many medical procedures, including nanorobots for drug transport, tissue measurements, and surgical procedures.

Machine learning classifier accelerates the development of cellular immunotherapies

A machine learning classifier developed by German Cancer Research Center (DKFZ) scientists has accelerated the development of personalized T cell therapies for cancer patients. The technology, called predicTCR, can identify tumor-reactive T cell receptors with 90% accuracy in a matter of days, regardless of tumor type.

Hopp Children's Cancer Center Heidelberg launches development cooperation to provide children worldwide with modern cancer diagnostics

The Hopp Children's Cancer Center Heidelberg has launched a development cooperation to establish modern molecular cancer diagnostics for children in low-income countries. Scientists from partner countries have received training and laboratory equipment to use an AI-based methylation analysis algorithm developed in Heidelberg.

Epigenetically acting drugs could support cancer immunotherapy

Scientists have discovered that epigenetically active cancer drugs can create new proteins on the surface of cancer cells, making them recognizable to the immune system. Treatment with these drugs induced thousands of new transcripts in lung cancer cells, including peptides that could be used to activate cytotoxic T cells.

Better distinguish chronic inflammation and cancer of the pancreas

Scientists have identified a DNA methylation pattern that can accurately diagnose pancreatic cancer, distinguishing it from chronic pancreatitis. The marker, which involves six specific methylation positions in the PRKCB gene, has been validated on tissue and blood samples, offering hope for improved diagnosis and treatment.

Obesity as a risk factor for colorectal cancer underestimated so far

A recent study has shown that obesity is a significant risk factor for colorectal cancer, with overweight individuals having a one-third higher risk of developing the disease. The study also found that unintentional weight loss in the years leading up to diagnosis may be an early indicator of colorectal cancer.

Epigenetic fingerprint as proof of origin for chicken, shrimp and salmon

Scientists at DKFZ developed a new detection method that analyzes epigenetic fingerprints to determine animal origin. The method uses DNA sequencing to identify chemical markers on the genome, allowing researchers to distinguish between free-range organic chicken, factory-farmed chicken, and other species.

Marker for therapy response in acute myeloid leukemia (AML) identified

Researchers at German Cancer Research Center have developed a marker that predicts which patients with acute myeloid leukemia (AML) will respond to the new therapy. The marker, known as the MAC score, measures the ratio of specific proteins in leukemia stem cells and can be used to determine treatment success.

Gut microbiome plays key role in response to CAR-T cell cancer immunotherapy

Researchers found that a healthy gut microbiome can predict the efficacy of CAR-T cell therapy in patients with B-cell lymphomas. The study identified specific microbiome features associated with improved treatment outcomes, but highlights the need for further investigation into the causal nature of this relationship.

A specific inhibitor allows to study an enigmatic enzyme

Scientists have synthesized a highly selective HDAC10 inhibitor that can be used to study the function of this enigmatic enzyme. The compound, DKFZ-748, suppresses the functions of HDAC10 in tumor cells, suggesting that it may remove acetyl groups from polyamines, making them usable by cancer cells for growth.

SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalJournal of the American Chemical Society·DateOct 10, 2022

Breaking down proteins: How starving cancer cells switch food sources

Researchers discovered a protein LYSET that enables cancer cells to digest extracellular proteins as an alternative food source under nutrient starvation conditions. This finding provides insight into the molecular pathways underlying cancer cell adaptation and could lead to new therapeutic strategies.

Inflammation accelerates aging of the hematopoietic system

A recent study published by the German Cancer Research Center found that inflammation in early life leads to a permanent decline in functional blood stem cells, suppressing their ability to regenerate. Mice exposed to inflammatory challenges developed clinically relevant features of aging, including anemia and decreased number of cells...

Cancer patients receiving immunotherapy: No evidence of increased risk for severe immune complication after COVID-19 vaccination

A study of 64 vaccinated and 26 unvaccinated cancer patients found that COVID-19 vaccination frequently triggers cytokine release syndrome-associated cytokines, but rarely causes symptoms. Vaccination appears to improve overall survival in vaccinated patients.

Why vaccination against malaria quickly loses its protective effect

A study found that malaria vaccines elicit a weak and limited immune response against the naturally occurring Plasmodium falciparum pathogen, resulting in short-lived protection. The researchers suggest that inducing a broader spectrum of T helper cells could generate longer-lasting immunity.

SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalScience Immunology·TypeExperimental study·DateJun 17, 2022

Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

Researchers discovered that neuroblastoma cells with high MYCN activity need cysteine, an amino acid crucial for protein production. Depriving these cells of cysteine triggers ferroptosis, a form of cell death, causing tumors to shrink. The study provides new insights into the treatment of aggressive neuroblastoma in children.

Vaccination against hereditary colorectal cancer successful in mice

Researchers at German Cancer Research Center successfully tested a protective vaccination against hereditary colorectal cancer in mice, achieving a significant delay in tumor development. Combining the vaccine with an anti-inflammatory drug further increased its effectiveness, showing promise for future clinical applications.